Brief: Waldencast Acquires Novaestiq Corp. And U.S. Rights To Leading Injectable Hyaluronic Acid Gel Line, Saypha, Under The Obagi Medical Brand
23/07/2025 11:47
July 23 (Reuters) - Waldencast PLC WALD.O: WALDENCAST ACQUIRES NOVAESTIQ CORP. AND U.S. RIGHTS TO LEADING INJECTABLE HYALURONIC ACID GEL LINE, SAYPHA®, UNDER THE OBAGI MEDICAL BRAND Source text: ID:nGNX7bkPdS Further company coverage: WALD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Waldencast
See all newsBrief: Waldencast PLC Files Form 15 To Deregister Its Securities And Suspend Its SEC Reporting Obligations Under The Exchange Act
Brief: Waldencast PLC Files Form 25 To Voluntary Delist From Nasdaq And Deregister Its Securities Under The Exchange Act
Brief: Waldencast Announces Sale Of Obagi Medical To Bridgepoint
Brief: Waldencast Announces Conclusion Of SEC Investigation
UK’s Waldencast posts flat Q4 revenue on Milk Makeup weakness, withholds outlook